- Home
- MDRR vs AIMD Comparison
MDRR vs AIMD Comparison
Compare MDRR & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- AIMD
- Stock Information
- Founded
- MDRR 2015
- AIMD 1984
- Country
- MDRR United States
- AIMD United States
- Employees
- MDRR N/A
- AIMD N/A
- Industry
- MDRR Real Estate Investment Trusts
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- AIMD Health Care
- Exchange
- MDRR Nasdaq
- AIMD Nasdaq
- Market Cap
- MDRR 18.0M
- AIMD 16.9M
- IPO Year
- MDRR 2018
- AIMD N/A
- Fundamental
- Price
- MDRR $13.98
- AIMD $2.27
- Analyst Decision
- MDRR
- AIMD
- Analyst Count
- MDRR 0
- AIMD 0
- Target Price
- MDRR N/A
- AIMD N/A
- AVG Volume (30 Days)
- MDRR 1.7K
- AIMD 41.7K
- Earning Date
- MDRR 11-06-2025
- AIMD 11-13-2025
- Dividend Yield
- MDRR 1.99%
- AIMD N/A
- EPS Growth
- MDRR N/A
- AIMD N/A
- EPS
- MDRR N/A
- AIMD N/A
- Revenue
- MDRR $10,098,461.00
- AIMD $113,037.00
- Revenue This Year
- MDRR N/A
- AIMD N/A
- Revenue Next Year
- MDRR N/A
- AIMD N/A
- P/E Ratio
- MDRR N/A
- AIMD N/A
- Revenue Growth
- MDRR 1.83
- AIMD 178.19
- 52 Week Low
- MDRR $9.55
- AIMD $1.78
- 52 Week High
- MDRR $15.00
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- MDRR 55.94
- AIMD 34.66
- Support Level
- MDRR $13.15
- AIMD $1.78
- Resistance Level
- MDRR $14.07
- AIMD $2.28
- Average True Range (ATR)
- MDRR 0.26
- AIMD 0.22
- MACD
- MDRR 0.02
- AIMD -0.03
- Stochastic Oscillator
- MDRR 88.27
- AIMD 26.09
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.